Evidence map›Paper›PMID 33194619›Full record

ArticleFrontiers in oncology2020

Host CD39 Deficiency Affects Radiation-Induced Tumor Growth Delay and Aggravates Radiation-Induced Normal Tissue Toxicity.

Alina V Meyer, Diana Klein, Simone de Leve, Klaudia Szymonowicz, Martin Stuschke, Simon C Robson, Verena Jendrossek, Florian Wirsdörfer

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Alina V MeyerMedical School, Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Essen, Germany.
Diana KleinMedical School, Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Essen, Germany.
Simone de LeveMedical School, Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Essen, Germany.
Klaudia SzymonowiczMedical School, Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Essen, Germany.
Martin StuschkeDepartment of Radiotherapy, University Hospital Essen, Essen, Germany.
Simon C RobsonDepartments of Medicine and Anesthesia, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard University, Boston, MA, United States.
Verena JendrossekMedical School, Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Essen, Germany.
Florian WirsdörferMedical School, Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Essen, Germany.
University of Duisburg-Essen · DEBeth Israel Deaconess Medical Center · USEssen University Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ectonucleoside triphosphate diphosphohydrolase (CD39)/5' ectonuclotidase (CD73)-dependent purinergic pathway emerges as promising cancer target. Yet, except for own previous work revealing a pathogenic role of CD73 and adenosine in radiation-induced lung fibrosis, the role of purinergic signaling for radiotherapy outcome remained elusive. Here we used C57BL/6 wild-type (WT), CD39 knockout (CD39

Indexed as

ATPcancerCD73ionizing radiationpurinergic signaling

Identifiers

PMID33194619
PMCPMC7649817
OpenAlexW3094626276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.